Inventor · disambiguated record
Vamsidhar Velcheti
Also filed as: VELCHETI VAMSIDHAR
16 granted patents·1 pending application·117 citations·filing 2016–2020
91Inventor score
Top patents by PatentIndex Score
17 records- 0196US10049770B2Prediction of recurrence of non-small cell lung cancerUNIV CASE WESTERN RESERVE·Filed 2016·Granted Aug 14, 2018·34 cites·20 claims
- 0293US10492723B2Predicting immunotherapy response in non-small cell lung cancer patients with quantitative vessel tortuosityUNIV CASE WESTERN RESERVE·Filed 2018·Granted Dec 3, 2019·21 cites·20 claims
- 0393US10078895B2Prediction of recurrence of non-small cell lung cancer with tumor infiltrating lymphocyte (TIL) graphsUNIV CASE WESTERN RESERVE·Filed 2016·Granted Sep 18, 2018·37 cites·20 claims
- 0485US10950351B2Methods and apparatus for predicting benefit from immunotherapy using tumoral and peritumoral radiomic featuresUNIV CASE WESTERN RESERVE·Filed 2019·Granted Mar 16, 2021·6 cites·19 claims
- 0585US10846367B2Predicting recurrence in early stage non-small cell lung cancer (NSCLC) with integrated radiomic and pathomic featuresUNIV CASE WESTERN RESERVE·Filed 2018·Granted Nov 24, 2020·6 cites·22 claims
- 0680US10956795B2Predicting recurrence in early stage non-small cell lung cancer (NSCLC) using spatial arrangement of clusters of tumor infiltrating lymphocytes and cancer nucleiUNIV CASE WESTERN RESERVE·Filed 2018·Granted Mar 23, 2021·4 cites·17 claims
- 0770US10902256B2Predicting response to immunotherapy using computer extracted features relating to spatial arrangement of tumor infiltrating lymphocytes in non-small cell lung cancerUNIV CASE WESTERN RESERVE·Filed 2019·Granted Jan 26, 2021·2 cites·20 claims
- 0870US10441225B2Predicting disease recurrence following trimodality therapy in non-small cell lung cancer using computed tomography derived radiomic features and clinico-pathologic featuresUNIV CASE WESTERN RESERVE·Filed 2018·Granted Oct 15, 2019·2 cites·20 claims
- 0969US10575774B2Predicting immunotherapy response in non-small cell lung cancer with serial radiomicsUNIV CASE WESTERN RESERVE·Filed 2017·Granted Mar 3, 2020·2 cites·29 claims
- 1065US11574404B2Predicting recurrence and overall survival using radiomic features correlated with PD-L1 expression in early stage non-small cell lung cancer (ES-NSCLC)UNIV CASE WESTERN RESERVE·Filed 2019·Granted Feb 7, 2023·1 cites·20 claims
- 1163US10441215B2Predicting immunotherapy response in non-small cell lung cancer with serial quantitative vessel tortuosityUNIV CASE WESTERN RESERVE·Filed 2018·Granted Oct 15, 2019·1 cites·31 claims
- 1262US11350901B2Recurrence prognosis and prediction of added benefit of adjuvant chemotherapy in early stage non-small cell lung cancer with radiomic features on baseline computed tomographyUNIV CASE WESTERN RESERVE·Filed 2018·Granted Jun 7, 2022·1 cites·20 claims
- 1358US2022226355A1Timed alternate administration of decitabine and 5-azacytidine for cancer treatmentCLEVELAND CLINIC FOUND·Filed 2020·Application pending·0 cites
- 1445US11055844B2Predicting response to immunotherapy using computer extracted features of cancer nuclei from hematoxylin and eosin (HandE) stained images of non-small cell lung cancer (NSCLC)UNIV CASE WESTERN RESERVE·Filed 2019·Granted Jul 6, 2021·0 cites·20 claims
- 1541US10839513B2Distinguishing hyperprogression from other response patterns to PD1/PD-L1 inhibitors in non-small cell lung cancer with pre-therapy radiomic featuresUNIV CASE WESTERN RESERVE·Filed 2019·Granted Nov 17, 2020·0 cites·20 claims
- 1639US10346975B2Computerized analysis of computed tomography (CT) imagery to quantify tumor infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC)UNIV CASE WESTERN RESERVE·Filed 2017·Granted Jul 9, 2019·0 cites·20 claims
- 1737US10458895B2Predicting response to pemetrexed chemotherapy in non-small cell lung cancer (NSCLC) with baseline computed tomography (CT) shape and texture featuresUNIV CASE WESTERN RESERVE·Filed 2017·Granted Oct 29, 2019·0 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when Vamsidhar Velcheti files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →